Evidence map›Paper›PMID 24898747›Full record

ReviewScience translational medicine2014

Human stem cells for modeling heart disease and for drug discovery.

Elena Matsa, Paul W Burridge, Joseph C Wu

Open access · greenAbstract readReview
In one paragraph

Review in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 215 citations in OpenAlex.

  1. Review
  2. A Novel Pak1 Activator Ameliorates ER Stress for HFpEF Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Elena MatsaStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA. Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Paul W BurridgeStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA. Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA 94305, USA. Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. joewu@stanford.edu.
Stanford University · USCalifornia Institute for Regenerative Medicine · US

Funding

Biorepository of Human iPSCs for Studying Dilated and Hypertrophic CardiomyopathyR24HL117756 · NHLBI · STANFORD UNIVERSITY · PI BUSTAMANTE, CARLOS DANIEL, SNYDER, MICHAEL P. · 2014 to 2018
$8.8M
Induced pluripotent stem cells in the understanding and treatment of heart diseaseU01HL099776 · NHLBI · STANFORD UNIVERSITY · PI LONGAKER, MICHAEL T, WU, JOSEPH C. · 2009 to 2015
$8.2M
Human Induced Pluripotent Stem Cells for Cardiovascular Disease ModelingR01HL113006 · NHLBI · STANFORD UNIVERSITY · PI WU, JOSEPH C. · 2012 to 2025
$6.8M
Modeling the role of the genome in chemotherapy induced cardiotoxicity using iPSCR00HL121177 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BURRIDGE, PAUL W. · 2015 to 2017
$743k
Modeling the role of the genome in chemotherapy induced cardiotoxicity using iPSCK99HL121177 · NHLBI · STANFORD UNIVERSITY · PI BURRIDGE, PAUL W. · 2014 to 2014
$89k
NHLBI NIH HHS K99 HL121177NHLBI NIH HHS R00 HL121177NHLBI NIH HHS R01 HL113006NHLBI NIH HHS R24 HL117756NHLBI NIH HHS U01 HL099776
6 · The paper itself

Abstract

A major research focus in the field of cardiovascular medicine is the prospect of using stem cells and progenitor cells for cardiac regeneration. With the advent of induced pluripotent stem cell (iPSC) technology, major efforts are also underway to use iPSCs to model heart disease, to screen for new drugs, and to test candidate drugs for cardiotoxicity. Here, we discuss recent advances in the exciting fields of stem cells and cardiovascular disease.

Indexed as

Drug DiscoveryModels, CardiovascularStem Cell TransplantationHeart DiseasesHumansStem CellsWound Healing

Identifiers

PMID24898747
PMCPMC4215696
OpenAlexW2063184176

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.